-

Allurion to Participate in the Jefferies Healthcare Conference

NATICK, Mass.--(BUSINESS WIRE)--Allurion, a company dedicated to ending obesity, today announced that it will be participating in the Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY on June 7-9, 2023. Shantanu Gaur, Allurion’s Chief Executive Officer, and Chris Geberth, Chief Financial Officer, will present on Friday, June 9, 2023 at 9:30 A.M. Eastern Time, and will be available for investor 1x1 meetings.

A webcast of the event will be available on the Allurion website.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

The Allurion Program combines a 4-month swallowable gastric balloon with a 6-month behavior change and weight-loss program that is supported by a suite of digital tools that facilitate monitoring, coaching and telehealth. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investor
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

Industry:

Allurion

Release Summary
Allurion to Participate in the Jefferies Healthcare Conference
Release Versions
English

Contacts

Media
Cedric Damour
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com

Investor
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

More News From Allurion

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarter and full year 2025. Management expects preliminary, unaudited results for the period as follows: Fourth quarter revenue of $3.3 million to $3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately $15 million Substantial improvement in operating expenses and operating...

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing their first 45 days of balloon therapy. The starting dose of tirzepatide was 2.5mg and...

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled study on the use of the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle intervention alone and its impact on weight loss and body composition. Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, results f...
Back to Newsroom